San Diego, CA and Melbourne, AUS – April 29, 2021 – Okogen, a clinical-stage specialty ophthalmic biotechnology company announced the interim analysis results from RUBY, the company’s Phase 2, double-masked, placebo-controlled clinical trial evaluating the safety and efficacy ...